Parkinson's Disease
Conditions
Keywords
Parkinson's Disease
Brief summary
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Interventions
None listed
Sponsors
AbbVie
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Base Infusion Rate | Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification). | Mean base infusion rate (ml/hour) will be assessed |
| Mean Low Infusion Rate | Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification). | Mean low infusion rate (ml/hour) will be assessed |
| Mean High Infusion Rate | Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification). | Mean high infusion rate (ml/hour) will be assessed |
Countries
Austria, Netherlands, Romania, Sweden
Contacts
Primary ContactABBVIE CALL CENTER
Outcome results
None listed